Skip to content
Review Open access

Precision immuno-oncology in triple-negative breast cancer: from PD-L1 to multimodal biomarkers, ADC–ICI combinations, and global real-world integration

Oct 2026 · Frontiers in Immunology · Vol 17 · 0 citations · 108 references
Medicine

TL;DR

This focused narrative review examines how biomarkers can distinguish established treatment eligibility from investigational strategies intended to address immune exclusion and resistance in triple-negative breast cancer.

Abstract

Immune checkpoint blockade improves outcomes in defined settings of triple-negative breast cancer (TNBC), but treatment failure does not identify a single biological mechanism or an interchangeable set of remedies. This focused narrative review examines how biomarkers can distinguish established treatment eligibility from investigational strategies intended to address immune exclusion and resistance. Randomized TNBC trials provide the clinical reference, while translational studies and trials in other malignancies are classified according to their applicability. PD-L1 testing remains relevant to first-line pembrolizumab combinations in advanced TNBC; it is not required to select patients for the KEYNOTE-522 early-stage regimen. Sacituzumab govitecan plus pembrolizumab is a United States-approved first-line option for PD-L1-positive advanced disease, but its comparative benefit establishes regimen-level efficacy rather than immunological synergy or reversal of checkpoint resistance. Proposed immune-priming effects remain specific to the ADC, experimental model and disease setting and should not be generalized across the ADC class. Stromal lymphocytes, spatial immune organization and circulating tumor DNA provide complementary biological or prognostic information without establishing a general replacement for PD-L1 or a validated rule for treatment escalation or omission. Strategies involving epigenetic modulation, adenosine blockade, DNA-damage signaling and local immune priming show different levels of evidence, including negative randomized findings. Particular caution is needed when extrapolating antigen-density thresholds and cellular-therapy outcomes from hematological malignancies. A useful biomarker framework must specify the disease setting, assay, proposed action and evidence that changing treatment improves outcomes. Prospective testing of these links, together with regimen-specific safety assessment and reliable access to established diagnostics, is necessary before resistance-directed combinations can be implemented routinely.

Read PDF

Similar papers

Meta-analysis Open access Oct 2026

PD-1/PD-L1 inhibitors combined with chemotherapy or as monotherapy versus chemotherapy alone or observation in triple-negative breast cancer: a systematic review and updated meta-analysis incorporating long-term survival data

Background Multiple RCTs have established PD-1/PD-L1 inhibitors as standard in triple-negative breast cancer (TNBC), but prior meta-analyses lacked complete setting coverage, mature long-term survival data, and a quantification of chemotherapy-backbone impact—critical given IMpassion130 (nab-paclitaxel, positive) vs. I...

Bing Guan, Ya-Wen Chen, Rong Zhou et al. · 0 citations
Case report Open access Oct 2026

[Systemic therapy for advanced triple-negative breast cancer in older women: strategy optimization and effectiveness of sacituzumab govitecan.]

Triple-negative breast cancer (TNBC) represents a major challenge for clinical oncologists, due to lack of therapeutical targets deriving from hormone-receptors and/or HER2 receptor expression. Moreover, TNBC typically shows a more aggressive clinical behavior and less responsiveness to traditional chemotherapy. Last y...

L. D'Onofrio · 0 citations
Open access Sep 2026

Trastuzumab plus nivolumab with gemcitabine and cisplatin as first-line therapy for HER2-positive unresectable biliary tract cancer: a phase 1b/2 trial

Biliary tract cancers (BTCs) are associated with poor outcomes despite recent incorporation of immune checkpoint inhibitors into first-line chemotherapy. Human epidermal growth factor receptor 2 (HER2) overexpression or amplification defines a therapeutically targetable subset of BTC but its integration into first-line...

Choong-kun Lee, Taek Chung, I. Kim et al. · 0 citations
Review Open access Oct 2026

Emerging immunotherapies in melanoma beyond immune checkpoint inhibitors: Vaccines, intralesional therapies, adoptive cell therapies, and T-cell engagers.

BACKGROUND Immune checkpoint inhibitors have transformed the management of melanoma, yet many patients do not achieve durable benefit. Novel immunotherapeutic strategies are being developed in both cutaneous and uveal melanoma. METHODS This narrative review summarizes four classes of emerging immunotherapies: persona...

I. Taglialatela, Leonardo Di Corcia, Andrea Boutros et al. · 0 citations
Open access Oct 2026

A phase II study combining radiotherapy and atezolizumab/nab-paclitaxel for inoperable or recurrent programmed death-ligand 1-positive triple-negative breast cancer: IMRad-Br study protocol and safety run-in.

BACKGROUND Triple-negative breast cancer (TNBC) is an aggressive subtype lacking estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expressions, with poor prognosis and limited treatment options. Studies have demonstrated the efficacy of immune checkpoint inhibitors (ICIs) combined w...

Hiroshi Ishiguro, N. Hoshi, Shin-Ei Noda et al. · 0 citations
Review Open access Nov 2026

Predictors of Benefit from Immune Checkpoint Inhibitors in Urothelial Carcinoma of the Bladder: The Limits of PD-L1 and the Rise of Circulating Tumor DNA-Guided Adjuvant Therapy.

Immune checkpoint inhibitors (ICIs) are established across the treatment continuum of urothelial carcinoma of the bladder, yet most patients derive no durable benefit. This narrative review appraises candidate predictors of ICI benefit in bladder urothelial carcinoma, distinguishing prognostic from predictive biomarker...

D. Novacescu, Mihael Musta, Radu Căprariu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.